<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30650163</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus.</ArticleTitle><Pagination><StartPage>e0210553</StartPage><MedlinePgn>e0210553</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0210553</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0210553</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) has emerged as a neurological virus causing life-threatening diseases in young children and infants. Although EV71 vaccines in development have presented promising results in several clinical trials, the identified key antigen for improving the broad protective efficacy of EV71 vaccines has not been well investigated. In this report, we show that different multiplicities of infection (MOIs) of the B4(E59) virus significantly affect EV71 vaccine production in a serum-free microcarrier bioreactor system. The antigens produced from high MOIs of 10-1 and 10-2 exhibited higher yield and more infectious full particle (FP) contents in the EV71 vaccines than those produced with low MOIs of 10-4 and 10-6, leading to better cross-neutralizing efficacy. The C4(E36) neutralization results showed that only antisera raised from EV71 FPs provided substantial neutralizing titers against C4(E36), whereas empty particles (EPs) of EV71 conferred no efficacy. Competitive ELISA showed that anti-FP mainly binds to FPs and that 20% of antibodies bind to EPs, whereas most anti-EP binds EPs, with only 10% antibodies binding to FPs. VP1-adsorbed anti-FP lost most of the virus neutralization efficiency, suggesting that the VP1 subunit of FP is the major immunogenic antigen determining the ability of the EV71 vaccine to elicit cross-neutralizing antibodies against EV71 virus subtypes. These findings demonstrate that the high-MOI production approach is significantly correlated with FP productivity, thereby improving the cross-neutralization efficacy of an EV71 vaccine and providing the basis for a better vaccine design against widespread EV71 viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chia-Ying</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Adimmune Corporation, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shu-Ling</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yung-Tsung</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Adimmune Corporation, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Hsuan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Adimmune Corporation, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Pei-Wen</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease and Vaccinology, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Juine-Ruey</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-4751-1217</Identifier><AffiliationInfo><Affiliation>Adimmune Corporation, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have the following interests: C.Y.W., Y.T.C., Y.H. Chen., and J.R.C. are employees of Adimmune Corporation. C.Y.W., Y.T.C., Y.H. Chen., and J.R.C. all have an equity interest in the company. S.L.Y. and Y.H. Chow. are employed by National Health Research Institutes, Taiwan. P.W.H. is employed by Academia Sinica, Taiwan. S.L.Y., Y.H. Chow., and P.W.H. have declared that no competing interests exist. This does not alter the authors&#x2019; adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30650163</ArticleId><ArticleId IdType="pmc">PMC6334917</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0210553</ArticleId><ArticleId IdType="pii">PONE-D-18-20789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, et al. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9(3):e1003240 Epub 2013/04/05. 10.1371/journal.ppat.1003240 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al.
A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nature Structural &amp; Molecular Biology. 2012;19:424
https://www.nature.com/articles/nsmb.2255#supplementary-information. </Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavappa R, Syed R, Flore O, Icenogle JP, Filman DJ, Hogle JM. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci. 1994;3(10):1651&#x2013;69. Epub 1994/10/01. 10.1002/pro.5560031005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031005</ArticleId><ArticleId IdType="pmc">PMC2142606</ArticleId><ArticleId IdType="pubmed">7849583</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, King A, et al. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J Virol. 1997;71(12):9743&#x2013;52. Epub 1997/11/26. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424&#x2013;9. Epub 2012/03/06. 10.1038/nsmb.2255 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JP Jr, Baden L, Pallansch MA, Anderson LJ. Enterovirus 71 infections and neurologic disease&#x2014;United States, 1977&#x2013;1991. J Infect Dis. 1994;169(4):905&#x2013;8. Epub 1994/04/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003;9(4):461&#x2013;8. Epub 2003/04/19. 10.3201/eid0904.020395 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, He Y, Yang H, Zhu J, Xu X, Dong J, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People&#x2019;s Republic of China. J Clin Microbiol. 2005;43(8):3835&#x2013;9. Epub 2005/08/06. 10.1128/JCM.43.8.3835-3839.2005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.8.3835-3839.2005</ArticleId><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Liao XY, Yu X, Li N, Zhu FC, Zeng Y, et al. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin Med J (Engl). 2010;123(13):1679&#x2013;84. Epub 2010/09/08. .</Citation><ArticleIdList><ArticleId IdType="pubmed">20819628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010;7:94 Epub 2010/05/13. 10.1186/1743-422X-7-94 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One. 2012;7(4):e34834 Epub 2012/04/25. 10.1371/journal.pone.0034834 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034834</ArticleId><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what&#x2019;s next? Emerg Health Threats J. 2013;6:19780 Epub 2013/10/15. 10.3402/ehtj.v6i0.19780 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu SC, Wang ET, Liu DP. Is a monovalent vaccine against enterovirus 71 sufficient? A review of enterovirus 71 vaccine development based on enterovirus surveillance in Taiwan. J Formos Med Assoc. 2013;112(9):508&#x2013;9. Epub 2013/10/02. 10.1016/j.jfma.2012.12.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2012.12.001</ArticleId><ArticleId IdType="pubmed">24079713</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829&#x2013;37. Epub 2014/02/28. 10.1056/NEJMoa1303224 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60(5):797&#x2013;803. Epub 2014/10/30. 10.1093/cid/ciu852 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT. The Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine Development. Int J Environ Res Public Health. 2016;13(9). Epub 2016/09/13. 10.3390/ijerph13090890 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1):4&#x2013;14. Epub 2017/02/09. 10.7774/cevr.2017.6.1.4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Jiang R, Hsieh YC, Tsao A, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8(11):e79783 Epub 2013/11/28. 10.1371/journal.pone.0079783 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One. 2013;8(11):e79599 Epub 2013/11/22. 10.1371/journal.pone.0079599 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CY, Lin YW, Kuo CH, Liu WH, Tai HF, Pan CH, et al. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse. PLoS One. 2015;10(8):e0136420 Epub 2015/08/20. 10.1371/journal.pone.0136420 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136420</ArticleId><ArticleId IdType="pmc">PMC4543551</ArticleId><ArticleId IdType="pubmed">26287531</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6(5):e20005 Epub 2011/05/24. 10.1371/journal.pone.0020005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed J M H. A simple method of estimating fifty percent endpoints. Am J Hygiene. 1938;27:493&#x2013;7.</Citation></Reference><Reference><Citation>Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One. 2012;7(11):e49973 Epub 2012/12/12. 10.1371/journal.pone.0049973 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YY, Chin KH, Chou CC, Lee CC, Shr HL, Gao FP, et al. Cloning, purification, crystallization and preliminary X-ray crystallographic analysis of XC847, a 3'-5' oligoribonuclease from Xanthomonas campestris. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005;61(Pt 10):902&#x2013;5. Epub 2006/03/03. 10.1107/S1744309105027132 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S1744309105027132</ArticleId><ArticleId IdType="pmc">PMC1991326</ArticleId><ArticleId IdType="pubmed">16511191</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chang HW, Yang G, Chiang JR, Chow YH, Sai IH, et al. Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods. 2011;176(1&#x2013;2):60&#x2013;8. Epub 2011/06/28. 10.1016/j.jviromet.2011.06.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2011.06.001</ArticleId><ArticleId IdType="pubmed">21704080</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362&#x2013;72. Epub 2011/04/20. 10.1016/j.vaccine.2011.04.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, Tasi HP, et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol. 2012;2012:831282 Epub 2012/09/26. 10.1155/2012/831282 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/831282</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow M, Baltimore D. Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats. Proc Natl Acad Sci U S A. 1982;79(23):7518&#x2013;21. Epub 1982/12/01. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC347371</ArticleId><ArticleId IdType="pubmed">6296837</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>